---
title: "Lysergide (DT120) in Generalized anxiety disorder: Natural history, survival, and mortality"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Natural history, survival, and mortality. Topics: Age of onset: DSM-5 generalized anxiety disorder in the World Mental Health Surveys, Age of onset and age at presentation: clinical reviews, Recovery and recurrence over 12 years: Harvard/Brown Anxiety Disorders Research Program, Remission in the first two years: Harvard Anxiety Research Program, and 8 further topics. 12 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Age of onset: DSM-5 generalized anxiety disorder in the World Mental Health Surveys

> “Onset before puberty was rare in these surveys, with only 5% of cases developing by age 13 years.”
> “There was a gradual, steady accumulation of new cases over the lifespan, with 25% of all cases emerging by 25 years, 50% of the cases emerging by 39 years, and 75% of the cases emerging by 53 years.”
> “Although the AOO distribution was shifted earlier for high-income countries (median AOO, 36 years) relative to middle- and low-income countries (median AOO, 43 years for both), the distributions were substantively similar across country groups”

Source: [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/)

<a id="topic-2.2.1.3-2"></a>

### Age of onset and age at presentation: clinical reviews

> “Most studies suggest a peak onset of GAD during late adolescence or early adulthood, but it can also present later in life.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “Generalised anxiety disorder, agoraphobia, and panic disorder exhibit more age-of-onset heterogeneity and sometimes present later in life.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

> “The median age at presentation is 30 years.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.3-3"></a>

### Recovery and recurrence over 12 years: Harvard/Brown Anxiety Disorders Research Program

> “Survival analyses revealed an overall chronic course for the majority of the anxiety disorders.”
> “In comparison, patients with generalized anxiety disorder, panic disorder with agoraphobia, and social phobia had much lower probabilities of achieving recovery over 12 years of follow-up (probabilities of 0.58, 0.48, and 0.37, respectively).”
> “The probability of having a recurrence of social phobia was 0.39 over 12 years, and the probability of recurrence in patients who had recovered from generalized anxiety disorder was 0.45 at the end of the 12 years.”
> “The average time spent in an illness episode during the study period was 80% for social phobia, 78% for panic disorder with agoraphobia, and 74% for generalized anxiety disorder.”
> “These data depict the anxiety disorders as insidious, with a chronic clinical course, low rates of recovery, and relatively high probabilities of recurrence.”

Source: [Bruce et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3272761/)

<a id="topic-2.2.1.3-4"></a>

### Remission in the first two years: Harvard Anxiety Research Program

> “Analysis of the 164 patients with GAD participating in the Harvard Anxiety Research Program.”
> “The likelihood of remission was 0.15 after one year and 0.25 after two years. The probability of becoming asymptomatic from all psychiatric symptoms was only 0.08.”
> “Likelihood of remission for GAD and any other comorbid condition after one year was half the annual remission rate for GAD alone.”

Source: [Yonkers et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8833684/)

<a id="topic-2.2.1.3-5"></a>

### Persistence of lifetime cases: World Mental Health Surveys

> “Generalized anxiety disorder typically begins in adulthood and persists over time, although onset is later and clinical course is more persistent in lower-income countries.”
> “Generalized anxiety disorder was more persistent in low-income (59.5%) and middle-income (56.1%) countries than in high-income countries (45.9%).”
> “Around the world, persistence was higher for earlier-onset GAD cases, for individuals with lower educational levels and family income, and for those not employed outside the home (ie, Other status, homemaker)”

Source: [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/)

<a id="topic-2.2.1.3-6"></a>

### Two-year remission and chronic recurrent course: Lancet seminar

> “Epidemiological studies show a relatively high ratio of 1 year to lifetime prevalence for anxiety disorders, indicative of a chronic recurrent nature.”
> “Among patients with only one anxiety disorder, 2 year remission rates were around 70% for panic disorder without agoraphobia and generalised anxiety disorder, decreasing to 50–55% for social anxiety disorder and panic disorder with agoraphobia and 43% for those with multiple anxiety disorders.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.3-7"></a>

### Course over 40 years of follow-up: hospital-admitted cohort in Madrid

> “Patients admitted with the diagnosis of anxiety states ('anxious thymopathy' ) to the Lopez Ibor Neuropsychiatric Research Institute between 1950 and 1961 were examined between 1984 and 1988 (n = 65).”
> “At first and second examinations 20% and 17% of subjects were diagnosed as GAD. Improvement was observed in 83%. GAD tended to disappear around age 50, but was replaced by somatization disorders.”
> “Lack of regular treatment compliance, female sex, and onset of GAD before age 25 were variables associated with a worse outcome.”

Source: [Rubio and Lopez-Ibor (2007)](https://pubmed.ncbi.nlm.nih.gov/17430415/)

<a id="topic-2.2.1.3-8"></a>

### Remission, recurrence, and prognosis: guideline and review statements

> “Anxiety can be a chronic condition characterized by periods of remission and recurrence. However, full recovery may occur.”

Source: [USPSTF anxiety screening recommendation (2023)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening)

> “The prognosis for patients with generalized anxiety disorder is guarded.”
> “Relapses are common, and patients often seek clinicians who can better address their needs.”
> “Unfortunately, despite optimal treatment, relapse rates are high.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.3-9"></a>

### Mortality: Danish total-population cohort

> “In total, 1066 (2.1%) people with anxiety disorders died during an average follow-up of 9.7 years. The risk of death by natural and unnatural causes was significantly higher among individuals with anxiety disorders (natural mortality rate ratio (MRR) = 1.39, 95% CI 1.28–1.51; unnatural MRR = 2.46, 95% CI 2.20–2.73) compared with the general population.”
> “Of those who died from unnatural causes, 16.5% had comorbid diagnoses of depression (MRR = 11.72, 95% CI 10.11–13.51).”
> “The risk for natural death was increased among patients with acute stress reaction, generalised anxiety disorder, panic disorder and social phobia.”
> “the risk for unnatural death was more than doubled in patients with acute stress reaction, generalised anxiety disorders, post-traumatic stress disorder and social phobia.”

Source: [Meier et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5082973/)

| Mortality rate ratio (95% CI), 2002 to 2011 | Generalised anxiety disorder |
| --- | --- |
| All causes | “1.62 (1.35–1.93)” |
| Unnatural causes | “2.55 (2.00–3.19)” |
| Natural causes | “1.64 (1.36–1.95)” |

Source: [Meier et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5082973/)

<a id="topic-2.2.1.3-10"></a>

### Suicidal ideation, attempts, and suicide: meta-analysis of 42 observational studies

> “Forty-two observational studies were included.”
> “Compared to those without anxiety, patients with anxiety were more likely to have suicidal ideations (OR = 2.89, 95% CI: 2.09, 4.00), attempted suicides (OR = 2.47, 95% CI: 1.96, 3.10), completed suicides (OR = 3.34, 95% CI: 2.13, 5.25), or have any suicidal behaviors (OR = 2.85, 95% CI: 2.35, 3.46).”
> “The increase in the risk of suicide was demonstrated for each subtype of anxiety except obsessive-compulsive disorder (OCD). The quality of this evidence is considered low to moderate due to heterogeneity and methodological limitations.”

Source: [Kanwar et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23408488/)

<a id="topic-2.2.1.3-11"></a>

### Suicidal thoughts and behaviors: meta-analysis of longitudinal prediction studies

> “Results indicated that anxiety is a statistically significant, yet weak, predictor of suicide ideation (OR=1.49, 95% CI: 1.18, 1.88) and attempts (OR=1.64, 95% CI: 1.47, 1.83), but not deaths (OR=1.01, 95% CI: 0.87, 1.18).”
> “Diagnoses of GAD, specific phobia, and social anxiety disorder were also significant predictors of suicide ideation.”
> “Agoraphobia, GAD, OCD, somatic symptom disorder, and specific phobia did not reach the level of statistical significance.”
> “Of note, only 4 suicide ideation prediction cases were used to generate overall ORs for PTSD, specific phobia, and social anxiety disorder, and only 2 cases were used for GAD, thereby limiting the conclusions we can draw from this set of analyses.”

Source: [Bentley et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4771521/)

<a id="topic-2.2.1.3-12"></a>

### Suicidal ideation by symptom severity: sponsor-funded National Health and Wellness Survey analysis

> “The analysis found that nearly half (48%) of respondents with severe GAD symptoms reported experiencing SI almost every day.”
> “Among those with GAD, 78% with moderate symptoms and 91% of those with severe symptoms reported SI within the past two weeks.”
> “The NHWS is an annual, nationally representative, online-based survey in which all data are self-reported.”
> “This analysis was funded by MindMed.”

Source: [MindMed suicidal ideation study announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/194/new-mindmed-retrospective-study-presented-at-psych-congress-2025-reveals-high-rates-of-suicidal-ideation-si-in-adults-with-generalized-anxiety-disorder-gad)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
